A Passaro1, P Mancuso2, S Gandini3, G Spitaleri4, V Labanca2, E Guerini-Rocco5,6, M Barberis5, C Catania4, E Del Signore4, F de Marinis4, F Bertolini2. 1. Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti, 435, 20141, Milan, Italy. antonio.passaro@ieo.it. 2. Laboratory of Hematology-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. 3. Division of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, Milan, Italy. 4. Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti, 435, 20141, Milan, Italy. 5. Division of Pathology and Laboratory Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy. 6. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Abstract
PURPOSE: Immunotherapy is a new standard first-line treatment for non-small cell lung cancers (NSCLC) with high programmed cell death-ligand 1 (PD-L1) expression (≥ 50%) and second-line treatment regardless of PD-L1 status, though not all patients benefit from this approach. Much effort is ongoing to identify robust prognostic and predictive biomarkers of response to immune checkpoint inhibitors, overcoming PD-L1 that appears limited in its ability to discriminate patient candidates to this new class of anticancer agents. The purpose of this research study is to identify potential new biomarkers for immunotherapy in lung cancer. METHODS: Fifty-three consecutive patients with advanced NSCLC treated with nivolumab were enrolled in the study. All the patients received a blood analysis looking for the relationship between different populations of baseline white blood cells and granulocytic myeloid-derived suppressor cells (Gr-MDSC) detected by flow cytometry, to identify and characterize patients with poor likelihood of benefit from nivolumab in NSCLC second-line setting, regardless of clinical feature and PDL1 expression. RESULTS: Univariate analysis showed that high baseline levels of Gr-MDSC and low baseline CD8/Gr-MDSC ratio are associated with significantly better (P = 0.02) response to immunotherapy treatment. Log-rank tests suggested a significant improvement in OS and PFS with high baseline levels of Gr-MDSC levels (≥ 6 cell/μl), low absolute neutrophil count (< 5840/μl), high eosinophil count (> 90 /μl), and NLR < 3. The multivariate analysis showed a statistically significant improvement for PFS (P = 0.003) and OS (P = 0.05) in favour of the identified good prognostic Gr-MDSC-linked asset group, compared with the poor prognosis group. CONCLUSION: The role of Gr-MDSC appears interesting as a potential biomarker in NSCLC patients receiving immune-checkpoint inhibitors. Further analyses are needed to confirmed and study in deep the role of these particular cells and their role in cancer response and progression during ICI therapy.
PURPOSE: Immunotherapy is a new standard first-line treatment for non-small cell lung cancers (NSCLC) with high programmed cell death-ligand 1 (PD-L1) expression (≥ 50%) and second-line treatment regardless of PD-L1 status, though not all patients benefit from this approach. Much effort is ongoing to identify robust prognostic and predictive biomarkers of response to immune checkpoint inhibitors, overcoming PD-L1 that appears limited in its ability to discriminate patient candidates to this new class of anticancer agents. The purpose of this research study is to identify potential new biomarkers for immunotherapy in lung cancer. METHODS: Fifty-three consecutive patients with advanced NSCLC treated with nivolumab were enrolled in the study. All the patients received a blood analysis looking for the relationship between different populations of baseline white blood cells and granulocytic myeloid-derived suppressor cells (Gr-MDSC) detected by flow cytometry, to identify and characterize patients with poor likelihood of benefit from nivolumab in NSCLC second-line setting, regardless of clinical feature and PDL1 expression. RESULTS: Univariate analysis showed that high baseline levels of Gr-MDSC and low baseline CD8/Gr-MDSC ratio are associated with significantly better (P = 0.02) response to immunotherapy treatment. Log-rank tests suggested a significant improvement in OS and PFS with high baseline levels of Gr-MDSC levels (≥ 6 cell/μl), low absolute neutrophil count (< 5840/μl), high eosinophil count (> 90 /μl), and NLR < 3. The multivariate analysis showed a statistically significant improvement for PFS (P = 0.003) and OS (P = 0.05) in favour of the identified good prognostic Gr-MDSC-linked asset group, compared with the poor prognosis group. CONCLUSION: The role of Gr-MDSC appears interesting as a potential biomarker in NSCLCpatients receiving immune-checkpoint inhibitors. Further analyses are needed to confirmed and study in deep the role of these particular cells and their role in cancer response and progression during ICI therapy.
Authors: P F Ferrucci; P A Ascierto; J Pigozzo; M Del Vecchio; M Maio; G C Antonini Cappellini; M Guidoboni; P Queirolo; P Savoia; M Mandalà; E Simeone; S Valpione; M Altomonte; F Spagnolo; E Cocorocchio; S Gandini; D Giannarelli; C Martinoli Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: Nicole Glodde; Tobias Bald; Debby van den Boorn-Konijnenberg; Kyohei Nakamura; Jake S O'Donnell; Sabrina Szczepanski; Maria Brandes; Sarah Eickhoff; Indrajit Das; Naveen Shridhar; Daniel Hinze; Meri Rogava; Tetje C van der Sluis; Janne J Ruotsalainen; Evelyn Gaffal; Jennifer Landsberg; Kerstin U Ludwig; Christoph Wilhelm; Monika Riek-Burchardt; Andreas J Müller; Christoffer Gebhardt; Richard A Scolyer; Georgina V Long; Viktor Janzen; Michele W L Teng; Wolfgang Kastenmüller; Massimiliano Mazzone; Mark J Smyth; Thomas Tüting; Michael Hölzel Journal: Immunity Date: 2017-10-17 Impact factor: 31.745
Authors: Deborah B Doroshow; Miguel F Sanmamed; Katherine Hastings; Katerina Politi; David L Rimm; Lieping Chen; Ignacio Melero; Kurt A Schalper; Roy S Herbst Journal: Clin Cancer Res Date: 2019-03-01 Impact factor: 12.531
Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan Journal: Science Date: 2015-03-12 Impact factor: 47.728
Authors: Heng Lin; Shuang Wei; Elaine M Hurt; Michael D Green; Lili Zhao; Linda Vatan; Wojciech Szeliga; Ronald Herbst; Paul W Harms; Leslie A Fecher; Pankaj Vats; Arul M Chinnaiyan; Christopher D Lao; Theodore S Lawrence; Max Wicha; Junzo Hamanishi; Masaki Mandai; Ilona Kryczek; Weiping Zou Journal: J Clin Invest Date: 2018-01-16 Impact factor: 14.808
Authors: Pier Francesco Ferrucci; Sara Gandini; Emilia Cocorocchio; Laura Pala; Federica Baldini; Massimo Mosconi; Gian Carlo Antonini Cappellini; Elena Albertazzi; Chiara Martinoli Journal: Oncotarget Date: 2017-08-01
Authors: Shadma Fatima; Yafeng Ma; Azadeh Safrachi; Sana Haider; Kevin J Spring; Fatemeh Vafaee; Kieran F Scott; Tara L Roberts; Therese M Becker; Paul de Souza Journal: Cancers (Basel) Date: 2022-03-25 Impact factor: 6.639